❯ Moderna and Merck’s mRNA Cancer Vaccine Succeeds in Phase 3; 1,137 Melanoma Patients Enrolled

FIRST P3 POSITIVEModerna and Merck announced that the personalized mRNA cancer vaccine intismeran autogene, combined with immunotherapy Keytruda, met its primary endpoint in 1,137 patients with fully resected high-risk melanoma: compared with Keytruda alone, it significantly extended recurrence-free survival and reduced the risk of distant metastasis. This is the first positive Phase 3 result for a personalized neoantigen therapy — and for any mRNA cancer therapy.

AI'S ROLETo be clear on where AI fits in: the workflow sequences each patient’s tumor, compares it with their healthy DNA, and an algorithm selects mutations suitable as immune targets, from which a vaccine is custom-built for that one patient. The model handles the target-selection step — not the invention of the therapy itself, so casting this as “AI cured cancer” would be misleading. The trial, coded INTerpath-001, enrolled patients with fully resected stage IIB to IV cutaneous melanoma; per the two companies’ announcement, no new safety signals were observed, with safety consistent with earlier combination studies.

NEXTThe Phase 3 success puts the two companies in position to apply for accelerated approval. The cost, lead time, and capacity of personalized manufacturing are the more realistic hurdles beyond regulatory approval.

PRODUCTION BOTTLENECKA vaccine made for a single patient tests how short the sequencing, design, and production chain can be compressed. If patient-specific customization becomes standard care, oncology scheduling, hospital procurement, and payer reimbursement models all have to be rewritten — production cost will be the constraint that binds before efficacy does. And for the AI drug-discovery narrative, this is the first time Phase 3 data can be cited, rather than just pretty molecular docking images — investors can use it to reprice the whole track starting today.

▪ SIGNALAI-involved drug R&D has posted Phase 3 data for the first time — the value isn’t in how smart the model is, but in the pipeline finally completing a full loop.